|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| Variables | 1 | 2 | 3 | 4 | 5 | 6 | 7 |
| 1. Years since diagnosis  | – | .34 | **.64\*\*** | .06 | -.18 | .03 | -.15 |
| 2. UPDRS part III  |  | –  | **.40\*** | –.04 | –.13 | -.25 | -.07 |
| 3. LED (mg/day) |  |  | – | .07 | –0.01 | –.05 | .02 |
| 4. Positive affect (pretest) |  |  |  | – | –.06 | .18 | .16 |
| 5. Negative affect (pretest) |  |  |  |  | – | –.11 | –.11 |
| 6. Facial expression (pretest) |  |  |  |  |  | – | **.48\*\*** |
| 7. Emotion recognition (pretest) |  |  |  |  |  |  | – |

###### **Supplementary Table 5.** Correlations between PD related variables and outcome variables.

*Note.* The table displays Pearson correlation coefficients for the relationship between PD related variables and outcome variables at pretestover all PD patients included in the study *(N* = 34). UPDRS-III, Unified Parkinson’s disease rating scale III (motor subscale). LED: Levodopa dose equivalent. Positive affect: mean score in the positive affect scale of the Positive and Negative Affect Schedule (PANAS) [Range 10–50]. Negative affect: mean score in the negative affect scale of the PANAS [Range 10–50]. Facial expression: mean facial electromyographic (EMG) activity during the facial expression task [transformed to T-values]. Emotion recognition: percentage of correct answers over all six emotions [Range 0-100]. \*\* *p* ≤ .010. \* *p* ≤ .050.